ADU S100
Alternative Names: ADU-S100; MIW 815Latest Information Update: 18 Aug 2023
At a glance
- Originator Aduro BioTech
- Developer Chinook Therapeutics; Novartis
- Class Antineoplastics; Nucleotides; Small molecules
- Mechanism of Action Immunostimulants; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer
- No development reported Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 28 Feb 2023 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Metastatic disease) in Australia (Intratumoural, Injection)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Metastatic disease) in Canada (Intratumoural, Injection)